Tag : HBV

  • CONFERENCE UPDATE
    B/F/TAF maintains HIV-1 and c suppression after switch from DTG + F/TDF: 48-week results from ALLIANCE OLE

    Approximately 3.1 million people worldwide live with concomitant human immunodeficiency virus-1 (HIV-1) and hepatitis B virus (HBV) infection. Current guidelines recommend tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF)-based antiretroviral therapies for most adults

  • CONFERENCE UPDATE
    Novel therapeutic vaccine VRON-0200 shows promise for HBV functional cure

    ​Chronic hepatitis B virus (HBV) infection remains a significant global health challenge despite the availability of preventative vaccines. To address the unmet need for functional cure, immune-based treatments are gaining attention. VRON-0200, a therapeutic vaccine, has been developed to enhance and broaden T cell responses through the expression of HBV core and polymerase antigens fused with a genetically encoded checkpoint modifier (HSV-1 glycoprotein D). Interim data from an ongoing phase 1b trial was presented by Professor Wong, Lai-Hung Grace from The Chinese University of Hong Kong at the AASLD Annual Meeting 2024.

    Professor Wong, Lai-Hung Grace

    Professor, Department of Medicine and Therapeutics, Centre for Liver Health, Faculty of Medicine, The Chinese University of Hong Kong

  • INDUSTRY ESSENTIALS
    Preventing mother-to-child transmission of HBV: Local recommendations on antenatal screening and management

    The 2024 guidelines developed by the Hong Kong College of Obstetricians and Gynaecologists (HKCOG) respond to the pressing public health challenge of hepatitis B virus (HBV) infection, which affects approximately 296 million people worldwide and is responsible for around 820,000 deaths each year, primarily from cirrhosis and hepatocellular carcinoma.